4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The Wilms' tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Angiogenesis, activation of metastasis and avoidance of immune destruction are important for cancer progression. These biological capabilities are, apart from cancer cells, mediated by different cell types, including endothelial, haematopoietic progenitor and myeloid-derived suppressor cells. We show here that all these cell types frequently express the Wilms' tumour suppressor Wt1, which transcriptionally controls expression of Pecam-1 (CD31) and c-kit (CD117). Inducible conditional knockout of Wt1 in endothelial, haematopoietic and myeloid-derived suppressor cells is sufficient to cause regression of tumour vascularization and an enhanced immune response, leading to decreased metastasis, regression of established tumours and enhanced survival. Thus, Wt1 is an important regulator of cancer growth via modulation of tumour vascularization, immune response and metastasis formation.

          Related collections

          Author and article information

          Journal
          Nat Commun
          Nature communications
          2041-1723
          2041-1723
          Dec 16 2014
          : 5
          Affiliations
          [1 ] Institute for Research on Cancer and Aging, Nice (IRCAN), Faculty of Medicine, University of Nice Sophia-Antipolis, CNRS UMR7284/INSERM U1081, 06107 Nice, France.
          [2 ] Division of Health Sciences, Osaka University Graduate School of Medicine, 565-0871 Osaka, Japan.
          [3 ] The Roslin Institute, University of Edinburgh, Easter Bush Campus, Midlothian EH25 9RG, UK.
          [4 ] 1] Institute for Research on Cancer and Aging, Nice (IRCAN), Faculty of Medicine, University of Nice Sophia-Antipolis, CNRS UMR7284/INSERM U1081, 06107 Nice, France [2] Department of Medical Genetics, CHU Nice, Nice 06202, France.
          [5 ] MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK.
          [6 ] 1] Institute for Research on Cancer and Aging, Nice (IRCAN), Faculty of Medicine, University of Nice Sophia-Antipolis, CNRS UMR7284/INSERM U1081, 06107 Nice, France [2] Department of Pathology, CHU Nice, 06002 Nice, France.
          Article
          ncomms6852
          10.1038/ncomms6852
          25510679
          1ed55e38-8ff2-493b-8491-226ec1bec447
          History

          Comments

          Comment on this article